Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus

FB Vincent, R Kandane-Rathnayake, AY Hoi, L Slavin, JD Godsell, AR Kitching, J Harris, C. L. Nelson, A. J. Jenkins, A. Chrysostomou, ML Hibbs, PG Kerr, M. Rischmueller, F Mackay, EF Morand

Research output: Contribution to journalArticleResearchpeer-review

Abstract

INTRODUCTION: We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).

METHODS: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.

RESULTS: uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.

CONCLUSIONS: uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.

Original languageEnglish
Pages (from-to)2029-2040
Number of pages12
JournalLupus
Volume27
Issue number13
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • A proliferation-inducing ligand (APRIL)
  • B-cell–activating factor from the tumour necrosis factor family (BAFF)
  • biomarker
  • lupus nephritis (LN)
  • monocyte chemoattractant protein 1 (MCP-1)
  • systemic lupus erythematosus (SLE)

Cite this

@article{ee66027c545e43f6881ed2481226f360,
title = "Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus",
abstract = "INTRODUCTION: We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).METHODS: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sj{\"o}gren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.RESULTS: uBAFF was detected in 12{\%} (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28{\%} (5/18) of SLE patients with active nephritis vs 5/67 (7{\%}) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32{\%} (25/77) and 46{\%} (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.CONCLUSIONS: uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.",
keywords = "A proliferation-inducing ligand (APRIL), B-cell–activating factor from the tumour necrosis factor family (BAFF), biomarker, lupus nephritis (LN), monocyte chemoattractant protein 1 (MCP-1), systemic lupus erythematosus (SLE)",
author = "FB Vincent and R Kandane-Rathnayake and AY Hoi and L Slavin and JD Godsell and AR Kitching and J Harris and Nelson, {C. L.} and Jenkins, {A. J.} and A. Chrysostomou and ML Hibbs and PG Kerr and M. Rischmueller and F Mackay and EF Morand",
year = "2018",
month = "11",
day = "1",
doi = "10.1177/0961203318804885",
language = "English",
volume = "27",
pages = "2029--2040",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "13",

}

Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. / Vincent, FB; Kandane-Rathnayake, R; Hoi, AY; Slavin, L; Godsell, JD; Kitching, AR; Harris, J; Nelson, C. L.; Jenkins, A. J.; Chrysostomou, A.; Hibbs, ML; Kerr, PG; Rischmueller, M.; Mackay, F; Morand, EF.

In: Lupus, Vol. 27, No. 13, 01.11.2018, p. 2029-2040.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus

AU - Vincent, FB

AU - Kandane-Rathnayake, R

AU - Hoi, AY

AU - Slavin, L

AU - Godsell, JD

AU - Kitching, AR

AU - Harris, J

AU - Nelson, C. L.

AU - Jenkins, A. J.

AU - Chrysostomou, A.

AU - Hibbs, ML

AU - Kerr, PG

AU - Rischmueller, M.

AU - Mackay, F

AU - Morand, EF

PY - 2018/11/1

Y1 - 2018/11/1

N2 - INTRODUCTION: We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).METHODS: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.RESULTS: uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.CONCLUSIONS: uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.

AB - INTRODUCTION: We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).METHODS: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.RESULTS: uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.CONCLUSIONS: uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.

KW - A proliferation-inducing ligand (APRIL)

KW - B-cell–activating factor from the tumour necrosis factor family (BAFF)

KW - biomarker

KW - lupus nephritis (LN)

KW - monocyte chemoattractant protein 1 (MCP-1)

KW - systemic lupus erythematosus (SLE)

UR - http://www.scopus.com/inward/record.url?scp=85055660461&partnerID=8YFLogxK

U2 - 10.1177/0961203318804885

DO - 10.1177/0961203318804885

M3 - Article

VL - 27

SP - 2029

EP - 2040

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 13

ER -